Browsing by keyword "specialty drugs"
Now showing items 1-2 of 2
-
Planning for the 2017 Specialty Drug Spend: When Costs are Steep but Pockets are Not DeepSpecialty drug spend increased by 15 percent to $121 billion in 2015 and is projected to rise even more. Budget-conscious payers need to implement novel management strategies that anticipate the cost of specialty medications before they’re available. A summary of efficacy data for high-impact specialty pipeline drugs expected to reach the market, including their place in therapy and budgetary impact. Also featured are strategies to mitigate costs of these cutting-edge medications and compare them to current therapy options.
-
State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015New direct-acting antivirals have the ability to cure chronic hepatitis C virus infection, but the costs of these treatments and the number of patients that need them could bring about financial struggles for health systems. This journal article examines Medicaid reimbursement for HCV medications in the periods before and after the aforementioned direct-acting antivirals were made available. The report also analyzes the the effect of Medicaid expansion on reimbursement for direct-acting antivirals.
